Clinical Trials and PLK1 Inhibitor Efficacy in Various Cancer Types
The success of PLK1 inhibitors drugs in clinical trials is proving pivotal in their development as a mainstream cancer treatment. PLK1 inhibitors have shown promise in disrupting the mitotic process in cancer cells, offering a targeted approach to treating aggressive tumors. As PLK1 overexpression is found in various cancers, including breast, lung, and prostate cancer, PLK1 inhibitors are...
0 Comments 0 Shares 136 Views 0 Reviews
Sponsored